Synergy CHC price target lowered to $7 from $10 at Roth Capital

Roth Capital analyst Sean McGowan lowered the firm’s price target on Synergy CHC (SNYR) to $7 from $10 and keeps a Buy rating on the shares. The company made good progress during Q3, broadening its distribution footprint for both supplements and beverages and continuing to expand geographically, though its results came up short of expectations due in part to cash being tight prior to the company’s recent equity raise, the analyst tells investors in a research note. Roth adds however that Synergy now has the capital needed to post significant growth in 2026.